Prognostic factors in patients with metastatic urothelial carcinoma who have treated with Atezolizumab.
Deniz TuralÖmer Fatih ÖlmezAhmet Taner SümbülNail ÖzhanBurcu ÇakarOsman KöstekMeltem EkenelMustafa ErmanHasan Şenol CoşkunFatih SelçukbiricikÖzge KeskinFatma Paksoy TürközKerem OruçSelami Bayramİrem BilgetekinBirol YıldızMehmet Ali Nahit ŞendurNail PaksoyAhmet DiricanDilek ErdemMeltem SelamÖzgür TanrıverdiSemra PaydaşZuhat UrakçıElif AtağSabri GüncanYüksel ÜrünAli AlkanAli Osman KayaDeniz Tataroğlu ÖzyükselerHalil TaşkaynatanMustafa YıldırımMüge SönmezTuğba BaşoğluŞeyda GündüzSaadettin KılıçkapMehmet ArtaçPublished in: International journal of clinical oncology (2021)
This model confirms the Bellmunt model with the addition of NLR > 3 and GFR less than 60 ml/min and can be associated with clinical trials that use immunotherapy in patients with bladder cancer.